Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $250,000.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin McCulloch sold 25,000 shares of the stock in a transaction that occurred on Monday, September 28th. The stock was sold at an average price of $10.00, for a total value of $250,000.00. Following the sale, the insider directly owned 1,614,208 shares in the company, valued at $16,142,080. This represents a 1.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

• On Tuesday, September 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.49, for a total value of $127,350.00.
• On Monday, August 3rd, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.02, for a total value of $120,300.00.
• On Wednesday, July 1st, Kevin McCulloch sold 90,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.03, for a total value of $722,700.00.

Xeris Biopharma Stock Performance

XERS opened at $9.25 on Friday. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45. Xeris Biopharma Holdings, Inc. has a 52-week low of $5.25 and a 52-week high of $11.33. The firm has a market cap of $1.69 billion, a P/E ratio of -84.09 and a beta of 0.53. The business’s fifty day moving average is $8.45 and its 200-day moving average is $7.29.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The company had revenue of $92.10 million during the quarter, compared to analyst estimates of $90.12 million. Sell-side analysts expect that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.

Institutional Investors Weigh In On Xeris Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the stock. KBC Group NV bought a new position in Xeris Biopharma in the 1st quarter valued at approximately $27,000. Allworth Financial LP acquired a new stake in Xeris Biopharma in the second quarter valued at approximately $34,000. State of Wyoming bought a new stake in shares of Xeris Biopharma during the second quarter worth $52,000. Integrated Wealth Concepts LLC bought a new stake in shares of Xeris Biopharma during the second quarter worth $74,000. Finally, Kingsview Wealth Management LLC acquired a new position in shares of Xeris Biopharma during the fourth quarter worth $78,000. 42.75% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Wall Street Zen raised shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Leerink Partners boosted their price objective on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research report on Thursday, September 10th. Finally, Barclays upped their target price on Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Xeris Biopharma presently has a consensus rating of “Hold” and a consensus price target of $12.80.

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology, and related rare or chronic conditions. The company uses proprietary formulation technologies designed to deliver medicines that are difficult to formulate or administer through conventional methods, including its XeriSol and XeriJect platforms.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection used to treat severe hypoglycemia; Keveyis (dichlorphenamide), a treatment for primary periodic paralysis; and Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with Cushing’s syndrome.